Connect with us

Subscribe

biotech

New drug could ‘halt’ Alzheimer’s

Amyloid plaques on axons of neurons affected by Alzheimer's disease

(USA)

A potentially game-changing Alzheimer’s therapy is to undergo clinical trials in America.

Pre-clinical studies carried out by M3 Biotechnology, headquartered in Seattle, of its NDX-1017 drug, showed it could ‘stop or slow’ the progression of the disease.

“Current drugs on the market for Alzheimer’s patients offer only symptomatic relief, whereas we anticipate NDX-1017 will slow, halt and potentially restore lost function. The pre-clinical studies suggest we are on the right path, and we are excited to advance a much-needed brain regenerative therapy to alleviate the suffering of millions afflicted by the disease, and their families, around the world,” said M3 CEO Leen Kawas.

Newsletter Signup

Staff reporter
Written By

Advertisement

Saliva test for Alzheimer’s

biotech

Bill Gates’ fund targets Alzheimer’s

start-ups

Biotechs target Alzheimer’s

biotech

Connect
Newsletter Signup